viDA Therapeutics Inc

Developing first-in-class drugs targeting granzymes for the treatment of disease characterized by epithelial dysfunction

Founded 2008 2 employees Venture round Total: $2.55M Biotechnology, Health Care +1

viDA Therapeutics Inc, founded in 2008, is focused on developing first-in-class drugs targeting granzymes for the treatment of inflammatory diseases characterized by epithelial barrier dysfunction. The company's lead drug, VTI-1002, is a potent inhibitor of Granzyme B (GzmB), a serine protease associated with epithelial dysfunction. viDA's initial programs concentrate on ophthalmology and dermatology, leveraging the potential of GzmB as a clinical target in these areas. The recent $1.80M Venture Round investment from BDC Venture Capital in 10 July 2013 underscores the interest in viDA's approach to addressing chronic inflammatory and autoimmune diseases. The company's strategy to advance a topical GzmB inhibitor into dermatology applications not only places emphasis on the clinical validation of GzmB but also indicates the potential for broader platform value. The vision of utilizing GzmB inhibitors orally/systemically further expands opportunities for addressing age-related inflammatory and autoimmune diseases. Overall, viDA Therapeutics Inc's focus on targeting granzymes for treating diseases characterized by epithelial dysfunction, alongside the recent investment, positions the company as a promising player in the biotechnology and healthcare industries, with the potential to deliver novel therapeutic solutions.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	$1.80M	1	BDC Venture Capital	10 Jul 2013
Venture Round	$750.00K	1	BDC Venture Capital	25 Apr 2013
Venture Round	Undisclosed	1	BDC Venture Capital	01 Jan 2012

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

$1.80M

BDC Venture Capital

10 Jul 2013

Venture Round

$750.00K

BDC Venture Capital

25 Apr 2013

Venture Round

Undisclosed

BDC Venture Capital

01 Jan 2012

FAQ About viDA Therapeutics Inc

Developing first-in-class drugs targeting granzymes for the treatment of disease characterized by epithelial dysfunction

viDA Therapeutics Inc was founded in 2008.

viDA Therapeutics Inc operates in Biotechnology, Health Care and Health and Wellness.

viDA Therapeutics Inc has approximately 2 employees.

viDA Therapeutics Inc has completed 3 funding rounds, raising a total of $2.55M. The latest funding stage is Venture round.

Top alternatives and competitors to viDA Therapeutics Inc include Invirsa, Inc, Entero Therapeutics (Nasdaq: ENTO). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

viDA Therapeutics Inc and Invirsa, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About viDA Therapeutics Inc

Funding Rounds & Investors (3)

viDA Therapeutics Inc Alternatives & Competitors

FAQ About viDA Therapeutics Inc